<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03996122</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A03281-54</org_study_id>
    <nct_id>NCT03996122</nct_id>
  </id_info>
  <brief_title>Research of Anatomo-functional Biomarkers in Schizophrenia</brief_title>
  <acronym>CLOZAREST</acronym>
  <official_title>Research of Anatomo-functional Biomarkers in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To objectify UR biomarkers, we propose a longitudinal follow-up of resistant patients with
      schizophrenia, starting before the onset of clozapine and including a multimodal brain
      imaging assessment (T1 and T2 weighted sequences, DTI, ASL-Perfusion, fMRI- Rest) associated
      with clinical and biological monitoring. In order to correct the MRI signal of clozapine
      hemodynamic effects, we will develop a new MRI methodology based on the concomitant
      collection of physiological parameters (blood pressure, electrocardiogram and respiration).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The identification of biomarkers of ultra-resistance (UR) to treatment in schizophrenia would
      allow earlier, better adapted and more effective personalized management of these patients,
      which would improve their functional prognosis.

      An early decrease in functional connectivity (FC) between some rest networks has recently
      been proposed as an UR biomarker by McNabb et al. Nevertheless, clozapine has, among its side
      effects, a direct cardiac action that profoundly modifies patient's hemodynamics. However,
      functional brain imaging techniques are based on BOLD effect which is dependent on these
      hemodynamic parameters. It is therefore not possible to say whether these differences in FC
      are inherent to the pathology or whether they are related to clozapine instauration which
      causes hemodynamic changes that may disturb BOLD signal.

      To objectify UR biomarkers, investigators propose a longitudinal follow-up of resistant
      patients, starting before clozapine instauration and including a multimodal brain imaging
      assessment (T1 and T2 weighted sequences, DTI, ASL-Perfusion, fMRI- Rest) associated with
      clinical and biological monitoring. In order to correct the MRI signal of clozapine
      hemodynamic effects, investigators will develop a new MRI methodology based on the
      concomitant collection of physiological parameters (blood pressure, electrocardiogram and
      respiration).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Anticipated">October 4, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 4, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>functional resonance imaging: resting-state</measure>
    <time_frame>baseline, Month 2 and Month 6</time_frame>
    <description>Functional connectivity comparison between baseline, month 2 and month 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BDNF samples</measure>
    <time_frame>baseline, Month 2 and Month 6</time_frame>
    <description>BDNF concentration comparison between baseline, month 2 and month 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional resonance imaging: ASL</measure>
    <time_frame>baseline, Month 2 and Month 6</time_frame>
    <description>Cerebral perfusion comparison between baseline, month 2 and month 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anatomical resonance imaging: DTI</measure>
    <time_frame>baseline, Month 2 and Month 6</time_frame>
    <description>Anatomical connectivity comparison between baseline, month 2 and month 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anatomical resonance imaging: T1</measure>
    <time_frame>baseline, Month 2 and Month 6</time_frame>
    <description>White and gray matter volumetric comparison between baseline, month 2 and month 6</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>resistant patients with schizophrenia</arm_group_label>
    <description>Age 18 - 60 years No MRI contraindication</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fMRI</intervention_name>
    <description>3 fMRI (TO, Month 2 and Month 6) 3 BDNF samples (TO, Month 2 and Month 6)</description>
    <arm_group_label>resistant patients with schizophrenia</arm_group_label>
    <other_name>BDNF samples</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      BDNF samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        resistant schizophrenia or schizoaffective disorder patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  schizophrenia or schizoaffective disorder (DSM 5)

          -  drug resistance

          -  written patient approval

          -  social security number in France

          -  curator or tutor approval if needed

        Exclusion Criteria:

          -  pregnancy

          -  other research participation

          -  neurological evolution disorder

          -  no MRI contraindication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anaïs Vandevelde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU of Caen, Esquirol</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anaïs Vandevelde, MD</last_name>
    <phone>0231064422</phone>
    <phone_ext>+33</phone_ext>
    <email>vandevelde-a@chu-caen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier Etard, MD</last_name>
    <phone>0231470200</phone>
    <phone_ext>+33</phone_ext>
    <email>etard-o@chu-caen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU CAEN Normandie</name>
      <address>
        <city>Caen</city>
        <state>Normandie</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anaïs Vandevelde, MD</last_name>
      <phone>231065062</phone>
      <phone_ext>+33</phone_ext>
      <email>vandevelde-a@chu-caen.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/30145382</url>
    <description>Abnormalities of fronto-subcortical pathways in schizophrenia and the differential impacts of antipsychotic treatment: a DTI-based tractography study</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/29042073</url>
    <description>Functional network dysconnectivity as a biomarker of treatment resistance in schizophrenia</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2019</study_first_posted>
  <last_update_submitted>June 21, 2019</last_update_submitted>
  <last_update_submitted_qc>June 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>schizo-affective disorder</keyword>
  <keyword>utra-resistance</keyword>
  <keyword>clozapine</keyword>
  <keyword>biomarker</keyword>
  <keyword>fMRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

